eGFR slope improvement with SGLT2 inhibitors is not statistically associated with changes in urinary protein in Japanese CKD patients: a single-center real-world analysis.
SGLT2 inhibitors protect kidneys through mechanisms beyond reducing protein loss, deepening understanding of how they work.
This Japanese single-center real-world study shows that SGLT2 inhibitors improve eGFR trajectories in CKD patients independently of proteinuria reduction, challenging the assumption that anti-proteinuric effects explain their renal protection. The finding contributes to mechanistic understanding of SGLT2i nephroprotection.
What the study was
- Study design
- Retrospective single-center real-world analysis
- Population
- Japanese CKD patients treated with SGLT2 inhibitors
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Clinical and experimental nephrology
Why it surfaced
Single-center Japanese SGLT2/CKD real-world analysis; mechanistically interesting but limited by single-center design and potential confounding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.